Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J6DQ
|
||||
| Former ID |
DNCL002655
|
||||
| Drug Name |
Tremelimumab
|
||||
| Drug Type |
Monoclonal antibody
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 3 | [1], [2] | ||
| Company |
AstraZeneca
|
||||
| CAS Number |
CAS 745013-59-6
|
||||
| Target and Pathway | |||||
| Target(s) | Cytotoxic T-lymphocyte protein 4 | Target Info | Modulator | [3] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | ||||
| T cell receptor signaling pathway | |||||
| Autoimmune thyroid disease | |||||
| Rheumatoid arthritis | |||||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | ||||
| Reactome | CTLA4 inhibitory signaling | ||||
| WikiPathways | Vitamin D Receptor Pathway | ||||
| T-Cell Receptor and Co-stimulatory Signaling | |||||
| Allograft Rejection | |||||
| Costimulation by the CD28 family | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02551159) Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8462). | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.